Prevention of hepatitis B reactivation in patients with hematologic malignancies treated with novel systemic therapies:Who and Why?  

作　　者：Matteo Tonnini Clara Solera Horna Luca Ielasi 

机构地区：[1]Department of Medical and Surgical Sciences,University of Bologna,Bologna 40138,Italy [2]Division of Internal Medicine,Hepatobiliary and Immunoallergic Diseases,IRCCS Azienda Ospedaliero-Universitaria di Bologna,Bologna 40138,Italy [3]Infectious Disease Unit,Azienda USL-IRCCS di Reggio Emilia,Reggio Emilia 42123,Italy [4]Department of Internal Medicine,Ospedale degli Infermi di Faenza,Faenza 48018,Italy

出　　处：《World Journal of Gastroenterology》2024年第5期509-511,共3页世界胃肠病学杂志（英文版）

摘　　要：The risk of reactivation in patients with chronic or past/resolved hepatitis B virus(HBV)infection receiving chemotherapy or immunosuppressive drugs is a wellknown possibility.The indication of antiviral prophylaxis with nucleo(t)side analogue is given according to the risk of HBV reactivation of the prescribed therapy.Though the advent of new drugs is occurring in all the field of medicine,in the setting of hematologic malignancies the last few years have been characterized by several drug classes and innovative cellular treatment.As novel therapies,there are few data about the rate of HBV reactivation and the decision of starting or not an antiviral prophylaxis could be challenging.Moreover,patients are often treated with a combination of different drugs,so evaluating the actual role of these new therapies in increasing the risk of HBV reactivation is difficult.First results are now available,but further studies are still needed.Patients with chronic HBV infection[hepatitis B surface antigen(HBsAg)positive]are reasonably all treated.Past/resolved HBV patients(HBsAg negative)are the actual area of uncertainty where it could be difficult choosing between prophylaxis and pre-emptive strategy.

关 键 词：Hepatitis B reactivation Hepatitis B virus Antiviral prophylaxis Hematologic malignancies Chimeric antigens receptor-T cell therapy Immune checkpoint inhibitors 

分 类 号：R512.62[医药卫生—内科学]